TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

OVERVIEW OF ACTIVITY
Gynecologic cancers comprise 5 primary cancers affecting the ovaries, uterine corpus (endometrial cancer), uterine cervix (cervical cancer), vulva and vagina. Of these, OC has continually been the most lethal. The American Cancer Society estimates that in 2016, 14,240 individuals will die of this disease, accounting for nearly 50% of deaths attributable to gynecologic cancers. As with many other tumors, patient outcomes are critically dependent upon effective multidisciplinary care, which often includes contributions from gynecologic, medical and radiation oncologists as well as pathologists, diagnostic radiologists, oncology nurses and psychosocial services. In addition to the disease- and treatment-related morbidity and mortality associated with gynecologic cancers, pain, fatigue, lymphedema, depression/anxiety, infertility/childbearing and sexual dysfunction are commonly occurring issues that must also be addressed in the care of these patients.

Oncology nurses play a pivotal role in supporting patients through their therapeutic journey and are essential to the delivery of a complete course of effective systemic treatment for OC. These video proceedings from the fifth part of an 8-part integrated CNE curriculum originally held at the 2016 ONS Annual Congress feature discussions with leading OC investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with OC.

LEARNING OBJECTIVES
- Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with OC.
- Demonstrate knowledge of existing guidelines and consensus statements regarding the rationale for genetic counseling/testing for all patients with newly diagnosed OC, regardless of family history.
- Develop an understanding of the initial and long-term treatment of advanced OC considering the role of the recently approved anti-VEGF antibody bevacizumab.
- Implement an evidence-based approach to the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of OC.
- Appreciate the recent FDA approval of olaparib for patients with highly refractory advanced OC, and safely integrate this agent into the clinical management of appropriate individuals.
- Recall ongoing trials of investigational approaches and agents in OC, and refer patients and obtain consent for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENTS
This educational activity for 1.6 contact hours is provided by Research To Practice during the period of August 2016 through August 2017. This activity is awarded 1.6 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/ONS2016/ILNA. ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an
acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

**FOR SUCCESSFUL COMPLETION**

This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSOvarian2016/CNE.

**CONTENT VALIDATION AND DISCLOSURES**

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

- **Paula J Anastasia, RN, MN, AOCN**  
  Gyn-Oncology Clinical Nurse Specialist  
  Cedars-Sinai Medical Center  
  Los Angeles, California  
  **Speakers Bureau:** Genentech BioOncology.

- **Lisa B Arvine, RN, MSN, ANP-BC, WHNP-BC**  
  Dana-Farber Cancer Institute  
  Boston, Massachusetts  
  No relevant conflicts of interest to disclose.

**Robert L Coleman, MD**  
Professor and Deputy Chairman  
Vice Chair, Clinical Research  
Ann Rife Cox Chair in Gynecology  
Department of Gynecologic Oncology and Reproductive Medicine  
Houston, Texas  

**Advisory Committee:** Abbott Laboratories, AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Cerulean Pharma Inc, Clovis Oncology, CritiTech Inc, Eisai Inc, Genentech BioOncology, Genmab, GlaxoSmithKline, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Merrimack Pharmaceuticals Inc, Nektar, Takeda Oncology, VentiRx Pharmaceuticals Inc; **Consulting Agreement:** Celgene Corporation; **Contracted Research:** Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, EMD Serono Inc, Janssen Biotech Inc, Merck, OncoMed Pharmaceuticals Inc, Takeda Oncology.

**Kathleen Moore, MD**  
Jim and Christy Everest Endowed Chair in Cancer Research  
Director, Oklahoma TSET Phase I Program  
Stephenson Cancer Center  
Associate Professor, Section of Gynecologic Oncology  
Director, Gynecologic Oncology Fellowship  
Department of Obstetrics and Gynecology  
University of Oklahoma Health Sciences Center  
Oklahoma City, Oklahoma  

**Advisory Committee:** Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc.


**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS** — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Genentech BioOncology.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2016
Expiration date: August 2017
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.
Select Publications


Coleman RL et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). *Proc SGO* 2015;Abstract 3.


